201 related articles for article (PubMed ID: 28432982)
1. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
Devic P; Amini-Adle M; Camdessanché JP; Dalle S
Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
[No Abstract] [Full Text] [Related]
2. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
3. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
Urosevic-Maiwald M; Mangana J; Dummer R
Ann Oncol; 2017 Jul; 28(7):1673-1675. PubMed ID: 28459947
[No Abstract] [Full Text] [Related]
4. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
5. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
[No Abstract] [Full Text] [Related]
6. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
[TBL] [Abstract][Full Text] [Related]
7. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
8. Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma.
Boukari F; Dugourd PM; Chassang M; Mondot L; Passeron T; Lacour JP; Montaudie H
Pigment Cell Melanoma Res; 2017 Mar; 30(2):262-264. PubMed ID: 27885826
[No Abstract] [Full Text] [Related]
9. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
11. Skin cancer: BRAF and MEK inhibitors-good news comes in twos!
Killock D
Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25331181
[No Abstract] [Full Text] [Related]
12. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
[TBL] [Abstract][Full Text] [Related]
13. Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
Loyson T; Werbrouck E; Punie K; Bonne L; Vandecaveye V; Bechter O
Melanoma Res; 2018 Apr; 28(2):147-150. PubMed ID: 29215399
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of BRAF and MEK in melanoma patients.
Infante JR; Swanton C
Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140
[No Abstract] [Full Text] [Related]
15. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
16. Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
Ribero S; Marra E; Tomasini CF; Fierro MT; Bombonato C; Longo C
Br J Dermatol; 2017 Apr; 176(4):1101-1102. PubMed ID: 27515562
[No Abstract] [Full Text] [Related]
17. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
18. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
19. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
Kaplan FM; Mastrangelo MJ; Aplin AE
J Invest Dermatol; 2010 Nov; 130(11):2669-71. PubMed ID: 20574441
[No Abstract] [Full Text] [Related]
20. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]